Contrarily, there is conflicting evidence regarding the sensitivity of thyroid carcinomas to BRAF inhibition, and it has been hypothesized that BRAFV600E thyroid carcinoma cells are less susceptible to BRAF inhibitors such as vemurafenib, because parallel signaling pathways are activated [17]. Here, BRAF is linked to thyroid gland carcinoma.